GSK Accused Of Ripping Off La. Medicaid Programs
GSK’s alleged off-label marketing of the drugs, which also include asthma drug Advair and seizure medication Lamictal, bilked the state out of “millions of dollars” in health program reimbursements, according to Louisiana Attorney General Buddy Caldwell.
“GSK’s egregious conduct and greed caused fraudulent claims to be submitted to the Louisiana Medicaid...
To view the full article, register now.